Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Other Non-Current Liabilities (2020 - 2026)

ADC Therapeutics has reported Other Non-Current Liabilities over the past 7 years, most recently at $18.5 million for Q1 2026.

  • Quarterly results put Other Non-Current Liabilities at $18.5 million for Q1 2026, up 316.1% from a year ago — trailing twelve months through Mar 2026 was $18.5 million (up 316.1% YoY), and the annual figure for FY2024 was $2.4 million, down 72.6%.
  • Other Non-Current Liabilities reached $18.5 million in Q1 2026 per ADCT's latest filing, up from $9.4 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $18.5 million in Q1 2026 and bottomed at $329000.0 in Q1 2023.
  • Median Other Non-Current Liabilities over the past 5 years was $6.5 million (2024), compared with a mean of $6.4 million.
  • The largest annual shift saw Other Non-Current Liabilities tumbled 99.62% in 2022 before it skyrocketed 1882.98% in 2024.
  • Over 5 years, Other Non-Current Liabilities stood at $838000.0 in 2022, then soared by 959.55% to $8.9 million in 2023, then crashed by 72.6% to $2.4 million in 2024, then surged by 286.11% to $9.4 million in 2025, then soared by 96.93% to $18.5 million in 2026.
  • Business Quant data shows Other Non-Current Liabilities for ADCT at $18.5 million in Q1 2026, $9.4 million in Q3 2025, and $7.2 million in Q2 2025.